<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501822</url>
  </required_header>
  <id_info>
    <org_study_id>TCRC-COVID</org_study_id>
    <nct_id>NCT04501822</nct_id>
  </id_info>
  <brief_title>One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia</brief_title>
  <official_title>One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the cardiac status of COVID-19 pneumonia
      patients during 1 year after discharge
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although COVID-19 manifests in most cases with respiratory symptoms, cardiovascular
      abnormalities is common in hospitalized patients. Patients with cardiovascular risk factors
      or established disease appear to have a worse prognosis. Myocardial dysfunction could be a
      direct manifestation of COVID-19. The investigators hypothesize that subjects after COVID-19
      pneumonia present myocardial and vascular remodeling during 1 year after discharge, even in
      the absence of prior cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic assessment of cardiac function</measure>
    <time_frame>up to one year</time_frame>
    <description>Echocardiographic assessment of global strain parameters at 3 and 12 months after discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>МАССЕ</measure>
    <time_frame>up to one year</time_frame>
    <description>Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative analysis of parenchymal lung damage</measure>
    <time_frame>up to one year</time_frame>
    <description>Describe the parenchymal lung damage through a quantitative analysis with chest CT at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercises capacity assessment</measure>
    <time_frame>up to one year</time_frame>
    <description>Six-min walk test at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of renal function</measure>
    <time_frame>up to one year</time_frame>
    <description>Measure of creatinine clearance at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of inflammation</measure>
    <time_frame>up to one year</time_frame>
    <description>Analysis for C-reactive protein at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of coagulation abnormality</measure>
    <time_frame>up to one year</time_frame>
    <description>Analysis for activated clotting time at 3 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life in first year after discharge</measure>
    <time_frame>up to one year</time_frame>
    <description>Assessment of the Short Form Health Survey (SF36) at 3 and 12 months after discharge</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Covid19</condition>
  <condition>Cardiac Complication</condition>
  <arm_group>
    <arm_group_label>Covid19 pneumonia patients</arm_group_label>
    <description>The study includes men and women ≥18 years old with documented COVID-19 pneumonia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Evaluation of clinical, instrumental and laboratory diagnostics tests</intervention_name>
    <description>During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests</description>
    <arm_group_label>Covid19 pneumonia patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study includes men and women ≥18 years old with documented COVID-19 pneumonia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with documented COVID-19 pneumonia

        Exclusion Criteria:

          -  Patients with cancer

          -  Impossible to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Yaroslavskaya, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tyumen Cardiology Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Yaroslavskaya, PhD</last_name>
    <phone>+7-912-395-50-40</phone>
    <email>yaroslavskayae@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Bessonov, PhD</last_name>
    <phone>+7-906-823-77-55</phone>
    <email>IvanBessnv@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Yaroslavskaya, PhD</last_name>
      <phone>+7-912-395-50-40</phone>
      <email>yaroslavskayae@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ivan Bessonov, PhD</last_name>
      <phone>+7-906-823-77-55</phone>
      <email>IvanBessnv@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT04501822/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

